Bavarian Nordic A/S  announced this week the initiation of full commercial operations in the U.S. only eight months after completing the acquisition of the manufacturing and global rights to Rabipur®/RabAvert® (Rabies...

Novavax, Inc., a late stage biotechnology company developing next-generation vaccines for serious infectious diseases, and Takeda Pharmaceutical Company Limited, today announced a partnership for the development,...

Two doses of an experimental vaccine to prevent coronavirus disease 2019 (COVID-19)  induced robust immune responses and rapidly controlled the coronavirus in the upper and lower airways of rhesus macaques...

Researchers from Singapore-MIT Alliance for Research and Technology (SMART), MIT’s research enterprise in Singapore, have found a practical way to induce a strong and broad immunity to the dengue...

 Valneva SE, a specialty vaccine company focused on prevention of diseases with major unmet needs, today announced positive initial results for its first Phase 2 study (VLA15-201) of Lyme disease vaccine...

Valneva SE, a specialty vaccine company focused on prevention against diseases with major unmet needs, today confirmed its participation in the UK government COVID-19 vaccine response program. Valneva...

An investigational vaccine, mRNA-1273, designed to protect against SARS-CoV-2, the virus that causes coronavirus disease 2019 (COVID-19), was generally well tolerated and prompted neutralizing antibody...

Osivax announced today that it has received over EUR 30M in public funding from different sources to support the development of universal vaccines against coronavirus and influenza. The Company’s proprietary oligoDOM®...

Altimmune, Inc. announced today dosing of the first patient in the Company’s Phase 1b clinical trial of NasoShield, a single dose intranasal anthrax vaccine candidate. “NasoShield is the only single...

A national study measuring parental attitudes toward vaccinations found 6.1% were hesitant about routine childhood immunizations while nearly 26% were hesitant about the influenza vaccine. “Our...